| |
|
|
|
| 1997-2001 |
|
 |
| |
Founded by Dr. Keelung Hong |
|
| |
|
|
| |
Seed-round of financing from Dr. Hong and TTY Biopharm |
|
| |
|
|
| |
Initiated development of Liposomal Amphotericin B |
|
| |
|
|
| |
The 1st Liposomal drug in Taiwan, Lipo-Dox®, entered clinical trial |
|
| |
|
|
| |
Collaboration with TTY Biopharm |
|
| |
|
|
|
| 2002 |
|
 |
| |
Lipo-Dox® has been approved as the prescription medication for Ovarian Cancer |
|
| |
|
|
| |
Expanded operation and relocated to Neihu Science Park |
|
| |
|
|
| |
Received NT$2M of SBIR from Ministry of Economic Affairs (MOEA) for NanoVNB® |
|
| |
|
|
| |
Received NT$20M of SBIR from MOEA for the development of "Anti-HCC immunoliposome" project |
|
| |
|
|
| |
2nd round of financing from TTY Biopharm and TLC Management team |
|
| |
|
|
|
| 2003 |
|
 |
| |
Expanded operation and relocated to Nankang Software Park |
|
| |
|
|
| |
Setup scale-up production in GMP plant |
|
| |
|
|
| |
NanoVNB® entered preclinical trial |
|
| |
|
|
| |
Received NT$6.7M of SBIR from MOEA for the development of anti-cancer NCE, Liposomal Vinorelbine |
|
| |
|
|
|
| 2004 |
|
|
| |
Lipo-Dox® has been approved as the prescription medication for Breast Cancer
|
|
| |
|
|
| |
Scale-Up and Phase I Clinical Trial conducted for NanoVNB® |
|
| |
|
|
| |
Set up Protein and Target Delivery Research Lab in the Incubation Center of Small and Medium Enterprise Administration (SMEA) |
|
| |
|
|
| |
Received NT$45M of "Leading Product Development Subsidy" from Industrial Development Bureau (IDB) of MOEA for Phase I clinical trial of NanoVNB® |
|
| |
|
|
| |
3rd round of financing led by Marvelex Inc. & PowerWorld Capital Management Corp. |
|
| |
|
|
|
| 2005 |
|
|
| |
Established TLC Biopharmaceuticals and lab in the U.S. |
|
| |
|
|
| |
Filed patent for TLC-X88 (later named as Lipotecan®) |
|
| |
|
|
| |
Conducted preclinical animal experiments for Lipotecan® |
|
| |
|
|
| |
Secured loan on preferential rates of NT$38million from IDB for "Phase I Clinical Trial of NanoVNB®" |
|
| |
|
|
|
| 2006 |
|
|
| |
NanoVNB® entered phase II clinical trial |
|
| |
|
|
|
| |
|
|
| |
Received NT$80M through "Industrial Technology Development Program" from MOEA for the development of Dual-functional anti-cancer drug |
|
| |
|
|
|
| 2007 |
|
|
|
| |
|
|
| |
Set up Preclinical PK and toxicity labs in the Incubation Center of Genomics Research Center, Academia Sinica. |
|
| |
|
|
| |
4th round of financing led by YFY and existing partners, Marvelex and PowerWorld Capital |
|
| |
|
|
| |
Secured loan on preferential rates of NT$40million from IDB for "Development of Dual Functional anti-cancer NCE (ME-TOO)" |
|
| |
|
|
|
| 2008 |
|
|
| |
Qualified by MOEA as a biotech company involved in NCE development, TLC is thus entitled to related subsidies |
|
| |
|
|
| |
IND for Lipotecan® (TLC-X88) was filed and approved by US FDA, the 1st anti-cancer NCE from Taiwan to achieve this milestone |
|
| |
|
|
| |
Lipotecan® entered Phase I Clinical Trial in U.S. and Taiwan |
|
| |
|
|
| |
Received NT$67M through "Industrial Technology Development Program" from MOEA for Lipotecan® |
|
| |
|
|
| |
Received NT$53M of "Leading Product Development Subsidy" from IDB, MOEA for ProFlow® |
|
| |
|
|
|
| |
|
|
|
| 2009 |
|
|
| |
Submitted NDA and ANDA for ProFlow® in Taiwan and Japan respectively |
|
| |
|
|
| |
5th round of financing co-led by current investor, Taiwan BioVenture Company and the world renowned biotech venture capital Burrill and Company |
|
| |
|
|
| |
Collaboration with Nihon Generic Co. (NGC) |
|
| |
|
|
| |
Secured loan on preferential rates of NT$31million from IDB for "Phase I Clinical Trial of Dual Functional Anti-cancer NCE, Lipotecan® " |
|
| |
|
|
| |
Bought office premises at NKSP on Lease-to-Purchase terms |
|
| |
|
|
|
| 2010 |
|
|
| |
Established TLC Biopharmaceuticals B.V. in Leiden Science Park, The Netherlands |
|
| |
|
|
| |
Lipotecan® was granted the orphan drug designation for the treatment of hepatocellular carcinoma (HCC) by both the European Commission and US FDA" |
|
| |
|
|
| |
Collaboration with Ildong Pharmaceutical |
|
| |
|
|
|
| 2011 |
|
|
| |
Listed on Emerging Market in Taiwan Stock Exchange (ticker number: 4152) |
|
| |
|
|
| |
Drug approval granted for ProFlow® in Taiwan |
|
| |
|
|
| |
Lipotecan® entered Phase II Clinical Trial in Taiwan |
|
| |
|
|
| |
Received NT$12M through "Industrial Technology Development Program" from MOEA for ProDexTM |
|
|
|
 |
back to top |
